Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 20Active not recruiting 7Not yet recruiting 2Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 86Breast 70Genitourinary 57Thoracic 49Lymphoid 39Other hematologic neoplasm 38CNS 27Tumor-Agnostic 24Head & Neck 22Gynecologic 20Dermatologic 16Plasma cell 15Myeloid 14Other solid neoplasm 10Sarcoma 7Endocrine 6Classical hematology 6Other 4Other neoplasm 1NET 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 1PT-100 dipeptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NET × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡